loading
前日終値:
$4.03
開ける:
$4.05
24時間の取引高:
4.30M
Relative Volume:
0.92
時価総額:
$901.42M
収益:
$38.03M
当期純損益:
$-146.40M
株価収益率:
-7.4808
EPS:
-0.52
ネットキャッシュフロー:
$-121.38M
1週間 パフォーマンス:
+11.60%
1か月 パフォーマンス:
+59.63%
6か月 パフォーマンス:
+28.55%
1年 パフォーマンス:
+41.64%
1日の値動き範囲:
Value
$3.83
$4.06
1週間の範囲:
Value
$3.37
$4.115
52週間の値動き範囲:
Value
$1.8906
$4.115

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name
名前
Abcellera Biologics Inc
Name
セクター
Healthcare (1163)
Name
電話
(604) 559-9005
Name
住所
150 W 4TH AVENUE, VANCOUVER
Name
職員
596
Name
Twitter
Name
次回の収益日
2024-11-18
Name
最新のSEC提出書
Name
ABCL's Discussions on Twitter

ABCL を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ABCL
Abcellera Biologics Inc
3.89 901.42M 38.03M -146.40M -121.38M -0.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
466.43 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
550.04 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.23 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
539.30 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
243.54 28.51B 3.81B -644.79M -669.77M -6.24

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-08-20 ダウングレード The Benchmark Company Buy → Hold
2024-02-22 アップグレード The Benchmark Company Hold → Buy
2023-12-05 開始されました KeyBanc Capital Markets Overweight
2023-11-06 ダウングレード The Benchmark Company Buy → Hold
2023-10-13 再開されました Piper Sandler Overweight
2023-02-28 開始されました Cowen Outperform
2022-12-15 開始されました Goldman Buy
2022-11-16 開始されました Truist Buy
2021-12-21 開始されました The Benchmark Company Buy
2021-11-19 開始されました Piper Sandler Overweight
2021-01-05 開始されました BMO Capital Markets Outperform
2021-01-05 開始されました Berenberg Buy
2021-01-05 開始されました Credit Suisse Outperform
2021-01-05 開始されました SVB Leerink Outperform
2021-01-05 開始されました Stifel Buy
すべてを表示

Abcellera Biologics Inc (ABCL) 最新ニュース

pulisher
Jun 13, 2025

AbCellera shareholders approve board election and auditor - Investing.com Australia

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera shareholders approve board election and auditor By Investing.com - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera Biologics Holds Annual Shareholder Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn (ABCL) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 12, 2025

ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

AbCellera Biologics (ABCL) Stands Out in Active Option Classes | - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

AbCellera Biologics (ABCL) Stands Out in Active Option Classes | ABCL Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 09, 2025

AbCellera Biologics Inc. (ABCL): A Bull Case Theory - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Squarepoint Ops LLC Acquires 44,367 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World

Jun 09, 2025
pulisher
Jun 03, 2025

AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

AbCellera Biologics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

Jun 03, 2025
pulisher
Jun 02, 2025

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today - AOL.com

Jun 02, 2025
pulisher
Jun 02, 2025

AbCellera (ABCL) Stock Rises on Health Canada Approval - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

AbCellera gains Health Canada nod for AD antibody trial By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - BioSpace

May 30, 2025
pulisher
May 30, 2025

AbCellera (ABCL) Gains Health Canada Approval for Clinical Trial - GuruFocus

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Receives Health Canada Approval for Trial - TipRanks

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Gets Health Canada Authorization for Phase 1 Trial of Dermatitis Treatment - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

AbCellera Receives Authorization from Health Canada to Initiate - GuruFocus

May 30, 2025
pulisher
May 30, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 | ABCL Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

AbCellera receives Health Canada authorization to initiate ABCL575 Phase 1 trial - TipRanks

May 30, 2025
pulisher
May 30, 2025

AbCellera gains Health Canada nod for AD antibody trial - Investing.com

May 30, 2025
pulisher
May 30, 2025

Health Canada Greenlights AbCellera's Novel Antibody Trial for Chronic Skin Disease Treatment - Stock Titan

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Holdings Boosted by Millennium Management LLC - Defense World

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential - MSN

May 30, 2025
pulisher
May 29, 2025

AbCellera Biologics Inc. raises US$100M in series A2 financing - McCarthy Tétrault

May 29, 2025
pulisher
May 20, 2025

13 Best Multibagger Stocks to Invest in Now - Insider Monkey

May 20, 2025
pulisher
May 18, 2025

Truist Financial Has Lowered Expectations for AbCellera Biologics (NASDAQ:ABCL) Stock Price - Defense World

May 18, 2025
pulisher
May 16, 2025

Truist cuts AbCellera stock target to $10, maintains Buy By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 16, 2025

Truist Securities Lowers Price Target for AbCellera Biologics (A - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Truist cuts AbCellera stock target to $10, maintains Buy - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

Truist Securities Lowers Price Target for AbCellera Biologics (ABCL) | ABCL Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Truist Adjusts Price Target for AbCellera (ABCL) Amid Strategic Shift | ABCL Stock News - GuruFocus

May 16, 2025
pulisher
May 15, 2025

Abcellera gains Canadian clearance for phase I study of ABCL-635 for vasomotor symptoms in menopause - BioWorld MedTech

May 15, 2025
pulisher
May 15, 2025

Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates - simplywall.st

May 15, 2025
pulisher
May 15, 2025

Analyst Forecasts Just Became More Bearish On AbCellera Biologics Inc. (NASDAQ:ABCL) - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

AbCellera to begin Phase 1 trial for menopause treatment By Investing.com - Investing.com Nigeria

May 15, 2025
pulisher
May 14, 2025

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - BioSpace

May 14, 2025
pulisher
May 14, 2025

AbCellera Biologics Gets Health Canada Approval for Phase 1 Trial of Menopause Treatment - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

AbCellera to begin Phase 1 trial for menopause treatment - Investing.com

May 14, 2025
pulisher
May 14, 2025

AbCellera (ABCL) Set to Launch Clinical Trial for Menopause Trea - GuruFocus

May 14, 2025
pulisher
May 14, 2025

AbCellera (ABCL) Set to Launch Clinical Trial for Menopause Treatment | ABCL Stock News - GuruFocus

May 14, 2025

Abcellera Biologics Inc (ABCL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.01
price up icon 1.80%
$35.71
price down icon 0.18%
$22.83
price up icon 0.62%
$96.88
price down icon 0.67%
$111.47
price up icon 0.91%
biotechnology ONC
$243.50
price up icon 0.85%
大文字化:     |  ボリューム (24 時間):